Molecular Genetic Tumour Panel* (dog)

LABOKLIN Service ID: 9986

For a more precise characterization of malignant tumours in dogs, a comprehensive analysis of the tumourgenome can be performed in selected cases.
Therapeutic:

  • Lack of known or conventional therapy concepts
  • (therapy-resistant) recurrence

Genomics-based targeted treatment can potentially provide a new treatment option (reglementation for off-label use of drugs).
Diagnostic:
  • A definitive cytological or (immuno)histological diagnosis was not possible

The molecular genetic signature can help to further narrow down the diagnosis (e.g. histiocytic neoplasia versus inflammation) and may also provide a treatment option.

Material

  • 15 smears rich in tumour cells (not covered)
  • Biopsies > 0.5 cm (formalin-fixed)
  • Tumour resectates (formalin-fixed)
  • Paraffin blocks with sufficient tumour material (paraffin rolls are NOT suitable)
    • NOT possible from decalcified tissue

Parameter

Examinations for 120 biomarkers (mutations)

Method

Next Generation Sequencing (NGS) (SearchLight DNA®)

Species list

dog

Duration

approx. 3 weeks

Remark

result

  • Summary of the molecular genetic results
  • Explanations and literature references on the biomarkers found
  • Monographs of the targeted medications will be provided if required and if they are available
  • If necessary, further advice on the treatment options found by e-mail directly from the oncologists in the USA

Limitations
  • A sufficient number of tumour cells and DNA quality are required
  • It is not always possible to isolate DNA in sufficient quantity and quality
  • Not every tumour has one of the 120 mutations tested
  • Mutations that open up a treatment option are not found in every case
  • Availability and cost of medication may vary from country to country
  • The medications may not be authorised for dogs in all countries
  • The efficacy of these medications in dogs is supported by varying degrees of evidence
  • The data on efficacy and side effects in the respective canine tumours is often incomplete

The decision and responsibility for the use of the medication listed in the report lies with the veterinarian in charge!
It is recommended that a specialised oncologist should be consulted in such cases.

* partner laboratory